Advertisement

Journal of Nuclear Cardiology

, Volume 10, Issue 3, pp 261–266 | Cite as

Long-term prognosis after a normal exercise stress Tc-99m sestamibi SPECT study

  • Abdou Elhendy
  • Arend Schinkel
  • Jeroen J. Bax
  • Ron T. van Domburg
  • Don Poldermans
Article

Abstract

Background

Patients with a normal stress technetium 99m sestamibi study were shown to have a favorable outcome at intermediate-term follow-up. However, long-term survival has not been studied. The aim of this study was to evaluate the incidence and predictors of mortality and cardiac events at long-term follow-up after a normal exercise stress sestamibi study.

Methods and Results

We studied 218 patients (mean age, 53 ± 10 years, 108 men) who had normal myocardial perfusion assessed by Tc-99m sestamibi single photon emission computed tomography at rest and during symptom-limited bicycle exercise stress test. Endpoints during a follow-up period of 7.4 ± 1.8 years were hard cardiac events (cardiac death and nonfatal myocardial infarction) and all-cause mortality. During follow-up, 13 patients died of various causes (cardiac death in 1 patient). Ten patients had nonfatal myocardial infarction (a total of 11 hard cardiac events). By multivariate analysis, independent predictors of cardiac events were history of coronary artery disease (X 2 = 5, P =.03) and lower exercise heart rate (X 2 = 12, P =.001). Independent predictors of all-cause mortality were age (X 2 = 4, P =.05) and exercise heart rate (X 2 = 5, P =.03). The annual mortality rate was 0.6% in the first 5 years and 1.8% between the sixth and eighth years. The annual hard cardiac event rate was 0.7% in the first 5 years and 1.5% between the sixth and eighth years. Receiver operating characteristic curves identified an exercise heart rate lower than 130 beats/min as the cutoff value that separated patients with regard to their risk for mortality and hard cardiac events.

Conclusions

It is concluded that the annual mortality and cardiac event rate is less than 1% during 5-year follow-up after a normal exercise sestamibi study. Therefore repeated testing would not be required unless there is a change in symptoms. Follow-up should be closer in patients with a history of coronary artery disease and in those who fail to achieve an exercise heart rate of 130 beats/min or greater.

Key Words

Exercise stress test sestamibi single photon emission computed tomography prognosis mortality coronary artery disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA guidelines for exercise testing: executive summary-a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). Circulation 1997;96:345–54.PubMedGoogle Scholar
  2. 2.
    Brown KA. Prognostic value of myocardial perfusion imaging: state of the art and new developments. J Nucl Cardiol 1996;3:516- 37.PubMedCrossRefGoogle Scholar
  3. 3.
    Iskander S, Iskandrian AE. Risk assessment using single-photon emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 1998;32:57–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Boyne TS, Koplan BA, Parsons WJ, et al. Predicting adverse outcome with exercise SPECT technetium-99m sestamibi imaging in patients with suspected or known coronary artery disease. Am J Cardiol 1997;79:270–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Hachamovitch R, Berman DS, Kiat H, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996;93:905–14.PubMedGoogle Scholar
  6. 6.
    Berman DS, Hachamovitch R, Kiat H, et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium- 99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1995;26:639–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Stratmann HG, Williams GA, Wittry MD, Chaitman BR, Miller DD. Exercise technetium-99m sestamibi tomography for cardiac risk stratification of patients with stable chest pain. Circulation 1994;89:615–22.PubMedGoogle Scholar
  8. 8.
    Soman P, Parsons A, Lahiri N, Lahiri A. The prognostic value of a normal Tc-99m sestamibi SPECT study in suspected coronary artery disease. J Nucl Cardiol 1999;6:252–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown KA, Altland E, Rowen M. Prognostic value of normal technetium-99m-sestamibi cardiac imaging. J Nucl Med 1994;35:554–7.PubMedGoogle Scholar
  10. 10.
    Raiker K, Sinusas AJ, Wackers FJ, Zaret BL. One-year prognosis of patients with normal planar or single-photon emission computed tomographic technetium 99m-labeled sestamibi exercise imaging. J Nucl Cardiol 1994;1:449–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Zanco P, Zampiero A, Favero A, et al. Myocardial technetium-99m sestamibi single-photon emission tomography as a prognostic tool in coronary artery disease: multivariate analysis in a long-term prospective study. Eur J Nucl Med 1995;22:1023–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Desideri A, Candelpergher G, Zanco P, et al. Exercise technetium 99m sestamibi single-photon emission computed tomography late after coronary artery bypass surgery: long-term follow-up. Clin Cardiol 1997;20:779–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Nallamouthu N, Araujo L, Russell J, Heo J, Iskandrian AE. Prognostic value of simultaneous perfusion and function assessment using technetium-99m sestamibi. Am J Cardiol 1996;78:562–4.PubMedCrossRefGoogle Scholar
  14. 14.
    Hachamovitch R, Berman DS, Kiat H, et al. Effective risk stratification using exercise myocardial perfusion SPECT in women: gender-related differences in prognostic nuclear testing. J Am Coll Cardiol 1996;28:34–44.PubMedCrossRefGoogle Scholar
  15. 15.
    Heller GV, Herman SD, Travin MI, et al. Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiacrelated hospital admissions. J Am Coll Cardiol 1995;26:1202–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Hachamovitch R, Berman DS, Kiat H, et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent man- agement in patients with or suspected of having myocardial ischemia. Am J Cardiol 1997;80:426–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Senior R, Raval U, Lahiri A. Prognostic value of stress dobutamine technetium-99m sestamibi single-photon emission computed tomography (SPECT) in patients with suspected coronary artery disease. Am J Cardiol 1996;78:1092–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Geleijnse ML, Elhendy A, van Domburg RT, et al. Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. J Am Coll Cardiol 1996;28:447–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Geleijnse ML, Elhendy A, van Domburg RT, et al. Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. Am J Cardiol 1996;77:1057–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Stratmann HG, Younis LT, Wittry MD, Amato M, Miller DD. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris. Am J Cardiol 1995;76:236–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Travin MI, Duca MD, Kline GM, et al. Relation of gender to physician use of test results and to the prognostic value of stress technetium 99m sestamibi myocardial single-photon emission computed tomography scintigraphy. Am Heart J 1997;134:73–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Miller DD. Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patients with stable chest pain who are unable to exercise. Am J Cardiol 1994;73:647–52.PubMedCrossRefGoogle Scholar
  23. 23.
    Calnon DA, McGrath PD, Doss AL, et al. Prognostic value of dobutamine stress technetium-99m-sestamibi single-photon emission computed tomography myocardial perfusion imaging: strati- fication of a high-risk population. J Am Coll Cardiol 2001;38:1511–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Elhendy A, Sozzi FB, van Domburg RT, et al. Relation among exercise-induced ventricular arrhythmias, myocardial ischemia, and viability late after acute myocardial infarction. Am J Cardiol 2000;86:723–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;300:1350–8.PubMedGoogle Scholar
  26. 26.
    Lauer MS, Francis GS, Okin PM, et al. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 1999;281:524–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Steinberg EH, Koss JH, Lee M, Grunwald AM, Bodenheimer MM. Prognostic significance from 10-year follow-up of a qualitatively normal planar exercise thallium test in suspected coronary artery disease. Am J Cardiol 1993;71:1270–3.PubMedCrossRefGoogle Scholar
  28. 28.
    Mandalapu BP, Amato M, Stratmann HG. Technetium Tc 99m sestamibi myocardial perfusion imaging: current role for evaluation of prognosis. Chest 1999;115:1684–94.PubMedCrossRefGoogle Scholar
  29. 29.
    Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol 1999;34:618–20.PubMedCrossRefGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2003

Authors and Affiliations

  • Abdou Elhendy
    • 2
  • Arend Schinkel
    • 1
  • Jeroen J. Bax
    • 2
  • Ron T. van Domburg
    • 2
  • Don Poldermans
    • 2
  1. 1.ThoraxcenterUniversity Hospital-DijkzigtRotterdamThe Netherlands
  2. 2.Department of Cardiology and Internal MedicineUniversity of Nebraska Medical CentreOmaha

Personalised recommendations